



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)




PRODUCT INFORMATION



Necrosulfonamide

Item No. 20844

CAS Registry No.: 1360614-48-7
Formal Name: (2E)-N-[4-[[[3-methoxy-2-pyrazinyl]amino]sulfonyl]phenyl]-3-(5-nitro-2-thienyl)-2-propenamide
MF: C₁₈H₁₅N₅O₆S₂
FW: 461.5
Purity: ≥95%
UV/Vis.: λ_{max}: 277, 366 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Necrosulfonamide is supplied as a crystalline solid. A stock solution may be made by dissolving the necrosulfonamide in the solvent of choice, which should be purged with an inert gas. Necrosulfonamide is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of necrosulfonamide in these solvents is approximately 20 and 25 mg/ml, respectively.

Necrosulfonamide is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, necrosulfonamide should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Necrosulfonamide has a solubility of approximately 0.5 mg/ml in a 1:50 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Necrosulfonamide is a small molecule that inhibits necroptosis by blocking mixed lineage kinase domain-like protein (MLKL), a key substrate of receptor-interacting serine-threonine kinase 3 (RIPK3).¹ Necrosulfonamide has been shown to prevent the MLKL-RIPK1-RIPK3 necrosome complex from interacting with downstream necrosis effectors.¹

Reference

1. Sun, L., Wang, H., Wang, Z., *et al.* Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. *Cell* **148**(1-2), 213-227 (2012).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/05/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM